PATH-MVI and US FDA to collaborate on malaria vaccine testing
This article was originally published in Scrip
Executive Summary
The PATH Malaria Vaccine Initiative is providing the US FDAwith about $1.5 million over three years to develop laboratory tests for evaluating malaria vaccines early in the development process. The collaboration, which is being carried out under a co-operative research and development agreement, will help develop tests to assess whether a vaccine candidate based on live, attenuated malaria parasites is safe enough to begin Phase I clinical testing. The project also will support development of other attenuated sporozoite vaccines, specifically those that are genetically attenuated, PATH-MVI said.